CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis

Journal of Bone and Mineral Research

Volumn 26, Issue 7, 2011, Pages 1533-1542

  Fromigue, Olivia ^a,b   Hamidouche, Zahia ^a,b   Vaudin, Pascal ^c   Lecanda, Fernando ^d   Patino, Ana ^d   Barbry, Pascal ^e,f   Mari, Bernard ^e,f   Marie, Pierre J ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITY OF NAVARRA   (Spain)

^e INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^f UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

BONE TUMOR; CCN1; LUNG; METASTASIS; STATIN

Indexed keywords

CYSTEINE RICH PROTEIN 61;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; CYR 61 GENE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BONE AND BONES; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYSTEINE-RICH PROTEIN 61; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPTANOIC ACIDS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PRENYLATION; PYRROLES;

EID: 79959507266     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.343     Document Type: Article

References (50)

1. Pompetti F, Rizzo P, Simon RM, et al. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem. 1996; 63: 37-50. (Pubitemid 26329785)
2. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH,. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 1993; 53: 16-18. (Pubitemid 23019370)
3. Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE,. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 1995; 55: 6244-6251.
4. Cao Y, Jia SF, Chakravarty G, de Crombrugghe B, Kleinerman ES,. The osterix transcription factor downregulates interleukin-1α expression in mouse osteosarcoma cells. Mol Cancer Res. 2008; 6: 119-126. (Pubitemid 351378172)
5. Cao Y, Zhou Z, de Crombrugghe B, et al. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res. 2005; 65: 1124-1128. (Pubitemid 40270133)
6. Thomas DM, Johnson SA, Sims NA, et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol. 2004; 167: 925-934. (Pubitemid 39628114)
7. Entz-Werle N, Stoetzel C, Berard-Marec P, et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer. 2005; 117: 349-355. (Pubitemid 41429557)
8. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP,. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008; 14: 2962-2969.
9. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10: 182-186. (Pubitemid 38524889)
10. Fromigue O, Hamidouche Z, Marie PJ,. Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs. J Pharmacol Exp Ther. 2008; 325: 595-600. (Pubitemid 351574795)
11. Fromigue O, Hamidouche Z, Marie PJ,. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem. 2008; 283: 30549-30556.
12. Fromigue O, Hay E, Modrowski D, et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006; 13: 1845-1856. (Pubitemid 44542398)
13. Yang GP, Lau LF,. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ. 1991; 2: 351-357.
14. Fournier B, Price PA,. Characterization of a new human osteosarcoma cell line OHS-4. J Cell Biol. 1991; 114: 577-583. (Pubitemid 21909825)
15. Rochet N, Dubousset J, Mazeau C, et al. Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int J Cancer. 1999; 82: 282-285. (Pubitemid 29293789)
16. Fromigue O, Lagneaux L, Body JJ,. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000; 15: 2211-2221.
17. Le Brigand K, Russell R, Moreilhon C, et al. An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomes. Nucleic Acids Res. 2006; 34: e87.
18. Casey PJ, Seabra MC,. Protein prenyltransferases. J Biol Chem. 1996; 271: 5289-92. (Pubitemid 26083855)
19. McTaggart SJ,. Isoprenylated proteins. Cell Mol Life Sci. 2006; 63: 255-267. (Pubitemid 43202309)
20. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ,. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res. 2003; 63: 5656-5668. (Pubitemid 37187458)
21. Sebti SM, Hamilton AD,. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 2000; 19: 6584-6593. (Pubitemid 32197696)
22. Rogers MJ,. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9: 2643-2658. (Pubitemid 37456015)
23. Hiraga T, Williams PJ, Mundy GR, Yoneda T,. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001; 61: 4418-4424. (Pubitemid 32685769)
24. Lee MV, Fong EM, Singer FR, Guenette RS,. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001; 61: 2602-2608. (Pubitemid 32685845)
25. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F,. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005; 104: 2522-2529. (Pubitemid 41691577)
26. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F,. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs. 2001; 12: 459-465. (Pubitemid 32643090)
27. Istvan E,. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler Suppl. 2003; 4: 3-8. (Pubitemid 38234501)
28. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008; 100: 134-139. (Pubitemid 351480564)
29. Beri A, Sural N, Mahajan SB,. Non-atheroprotective effects of statins: a systematic review. Am J Cardiovasc Drugs. 2009; 9: 361-370.
30. Gonyeau MJ, Yuen DW,. A clinical review of statins and cancer: helpful or harmful? Pharmacotherapy. 30: 177-194.
31. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF,. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1998; 95: 6355-6360. (Pubitemid 28249016)
32. Bleau AM, Planque N, Perbal B,. CCN proteins and cancer: two to tango. Front Biosci. 2005; 10: 998-1009.
33. Menendez JA, Mehmi I, Griggs DW, Lupu R,. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 2003; 10: 141-152. (Pubitemid 36758643)
34. Lin SK, Kok SH, Lee YL, et al. Simvastatin as a novel strategy to alleviate periapical lesions. J Endod. 2009; 35: 657-662.
35. Lechner A, Schutze N, Siggelkow H, Seufert J, Jakob F,. The immediate early gene product hCYR61 localizes to the secretory pathway in human osteoblasts. Bone. 2000; 27: 53-60. (Pubitemid 30365077)
36. Si W, Kang Q, Luu HH, et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol. 2006; 26: 2955-2964.
37. Schutze N, Schenk R, Fiedler J, Mattes T, Jakob F, Brenner RE,. CYR61/CCN1 and WISP3/CCN6 are chemoattractive ligands for human multipotent mesenchymal stroma cells. BMC Cell Biol. 2007; 8: 45.
38. Sandberg A,. Random break points in normal individuals as well as genetic disorder patients. The Chromosomes in Human Cancer and Leukemia. New York: Elsevier; 1980: 567-596.
39. Murata H, Kusuzaki K, Takeshita H, et al. Aberrations of chromosomes 1 and 17 in six human osteosarcoma cell lines using double-target fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998; 107: 7-10. (Pubitemid 28506739)
40. Martirosyan A, Clendening JW, Goard CA, Penn LZ,. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer. 10: 103.
41. Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B,. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol. 2007; 79: 240-243. (Pubitemid 47231166)
42. van der Spek E, Bloem AC, Sinnige HA, Lokhorst HM,. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica. 2007; 92: e130-1.
43. van der Spek E, Bloem AC, van de Donk NW, et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica. 2006; 91: 542-545.
44. Wittig R, Nessling M, Will RD, et al. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res. 2002; 62: 6698-6705. (Pubitemid 35364140)
45. Gery S, Xie D, Yin D, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res. 2005; 11: 7243-7254. (Pubitemid 41507681)
46. Lin MT, Chang CC, Chen ST, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem. 2004; 279: 24015-24023.
47. Marra M, Santini D, Meo G, et al. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer. 2009; 125: 2004-2013.
48. Nguyen N, Kuliopulos A, Graham RA, Covic L,. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res. 2006; 66: 2658-2665.
49. Manara MC, Perbal B, Benini S, et al. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 2002; 160: 849-859. (Pubitemid 34224575)
50. Perbal B, Zuntini M, Zambelli D, et al. Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res. 2008; 14: 701-709. (Pubitemid 351231150)